Hepatitis for NEET PG — Serology and Management 2026

Version 1.0 — Published March 2026

Hepatitis is inflammation of the liver — most commonly caused by hepatotropic viruses (A through E) but also by drugs, alcohol, autoimmune mechanisms, and metabolic conditions. In NEET PG, hepatitis B serology interpretation alone accounts for 1–2 predictable questions per paper, making it one of the highest-yield topics across medicine and microbiology. The student who masters the serology table and can read any marker combination on sight has secured reliable marks.

This guide covers every hepatitis subtype with the virology, serology, and management details that NBE tests. Pair this with MCQ practice on the Medicine subject hub and cross-reference high-yield microbiology topics for the virology classification angle.

Hepatitis viruses — taxonomy and transmission

The five hepatotropic viruses (A through E) differ in their genome, transmission route, chronicity risk, and clinical significance — and these differences are tested directly in NEET PG.

Key distinctions for NEET PG:

• Only DNA virus: HBV (all others are RNA)
• Highest chronicity: HCV (70–85% of infections become chronic)
• Requires co-infection: HDV needs HBV surface antigen to assemble its virion (defective virus)
• Highest mortality in pregnancy: HEV (15–25% in third trimester)
• Most common cause of post-transfusion hepatitis: HCV (before screening; now HBV in endemic areas)

Hepatitis B serology — the complete interpretation

Hepatitis B serology is the pattern-based interpretation of six markers that define the stage of HBV infection — and this is arguably the single most predictable topic in NEET PG medicine and microbiology.

The six markers

Serology interpretation table — the master reference

The window period — the most tested trap

The window period is the interval between disappearance of HBsAg and appearance of anti-HBs. During this window:

• HBsAg = negative (surface antigen has been cleared)
• Anti-HBs = not yet positive (antibody production is ongoing)
• IgM anti-HBc = the ONLY positive marker

Clinical significance: A patient in the window period will test negative on routine HBsAg screening but is still infected. This is why blood banks test for anti-HBc in addition to HBsAg.

HBV DNA — the quantitative marker

HBV DNA (viral load) is measured by PCR and is the most direct indicator of viral replication:

• >20,000 IU/mL in HBeAg-positive chronic HBV → indicates treatment
• >2,000 IU/mL in HBeAg-negative chronic HBV → indicates treatment
• Undetectable HBV DNA = virological suppression (goal of therapy)

Chronic HBV treatment

Treatment indications: HBV DNA above threshold + ALT elevated + significant fibrosis (or cirrhosis regardless of ALT).

Hepatitis C — diagnosis and DAA therapy

Hepatitis C is a chronic viral infection caused by an RNA virus of the Flaviviridae family — notable for its high chronicity rate (70–85%) and its transformation by direct-acting antiviral (DAA) therapy from a difficult-to-treat chronic disease to a curable infection.

Epidemiology in India: Genotype 3 is the most common in India (60–70%), followed by genotype 1 (20–30%). Prevalence: 0.5–1.5% (lower than HBV but significant due to high chronicity).

Diagnosis:

1. Anti-HCV antibody (screening) — ELISA. Positive result needs confirmation.
2. HCV RNA PCR (confirmatory + quantitative) — confirms active infection and measures viral load.
3. HCV genotyping — determines treatment duration and regimen (less important with pan-genotypic DAAs).

Key point: Anti-HCV remains positive even after cure (unlike HBsAg which clears). Therefore, HCV RNA PCR is the test to confirm active infection and to confirm cure (SVR12).

DAA therapy — the revolution

DAA drug targets:

• NS5B polymerase inhibitors: Sofosbuvir (nucleotide analogue — backbone of most regimens)
• NS5A inhibitors: Velpatasvir, Ledipasvir, Daclatasvir, Pibrentasvir
• NS3/4A protease inhibitors: Glecaprevir, Grazoprevir

SVR12 (Sustained Virologic Response at 12 weeks post-treatment): Undetectable HCV RNA at 12 weeks after completing therapy = CURE. Relapse after SVR12 is extremely rare (<1%).

NBE point: Interferon-based therapy (PEG-IFN + ribavirin) is OBSOLETE for HCV. DAAs have replaced it entirely. However, know that ribavirin is still teratogenic (pregnancy category X) and causes hemolytic anemia.

Hepatitis in pregnancy

Hepatitis in pregnancy is a high-yield crossover topic between medicine and obstetrics — with HEV's catastrophic mortality and HBV's vertical transmission prevention being the two most tested angles.

HEV in pregnancy — the Indian context

• HEV genotype 1 (endemic in India) causes fulminant hepatic failure in pregnant women
• Mortality: 15–25% in third trimester (vs <1% in non-pregnant individuals)
• Mechanism: Immune modulation in pregnancy + direct hepatocyte cytopathic effect
• No specific antiviral treatment — supportive care, monitor for coagulopathy and encephalopathy
• Prevention: Clean water, sanitation. No widely available vaccine (Hecolin approved in China, not available in India).

HBV vertical transmission prevention

• Risk of transmission: HBeAg-positive mother: 70–90% risk. HBeAg-negative mother: 10–40% risk.
• Risk of chronicity in neonates: 90% of neonates infected at birth develop chronic HBV (immature immune system cannot clear the virus)

Prevention protocol (tested repeatedly):

1. HBIG (hepatitis B immunoglobulin) + HBV vaccine: within 12 hours of birth
2. Complete the 3-dose vaccine series (0, 1, 6 months)
3. Test infant at 9–12 months: HBsAg and anti-HBs
4. Tenofovir for mothers with HBV DNA >200,000 IU/mL in third trimester (reduces viral load before delivery)

Breastfeeding: NOT contraindicated in HBV-positive mothers if infant has received HBIG + vaccine.

Drug-induced hepatitis

Drug-induced liver injury (DILI) is hepatotoxicity caused by medications — a critical topic tested in both pharmacology and medicine, where the examiner presents a clinical vignette of liver injury after starting a specific drug.

R-value for classifying DILI pattern:

• R = (ALT/ULN) / (ALP/ULN)
• R >5: Hepatocellular
• R <2: Cholestatic
• R 2–5: Mixed

Acute vs chronic liver failure

Acute liver failure (ALF)

Acute liver failure is the rapid onset of severe hepatic dysfunction (coagulopathy + encephalopathy) in a patient WITHOUT pre-existing liver disease — developing within 26 weeks of the first sign of liver disease.

Causes in India: HEV (most common), HAV, HBV, drug-induced (acetaminophen, ATT drugs), Wilson disease (in young patients)

Classification by onset:

• Hyperacute: <7 days (acetaminophen, HAV — better prognosis paradoxically)
• Acute: 7–21 days
• Subacute: 21 days – 26 weeks (worst prognosis)

Management: ICU care, N-acetylcysteine (even for non-acetaminophen ALF — some evidence of benefit), monitor ICP (cerebral edema is the leading cause of death), liver transplant if King's College criteria met.

Chronic liver disease and cirrhosis

Chronic liver failure results from progressive hepatocyte loss and fibrosis over months to years — culminating in cirrhosis with portal hypertension.

Complications of cirrhosis:

• Portal hypertension → esophageal varices (bleeding), splenomegaly, caput medusae, hemorrhoids
• Ascites → serum-ascites albumin gradient (SAAG) >=1.1 indicates portal hypertension
• Hepatic encephalopathy → flapping tremor (asterixis), confusion, coma. Treat with lactulose + rifaximin.
• Hepatorenal syndrome → renal vasoconstriction in advanced cirrhosis. Type 1 (rapidly progressive, median survival 2 weeks without treatment).
• Hepatocellular carcinoma → surveillance with AFP + ultrasound every 6 months in cirrhotics

Vaccination schedules

Hepatitis vaccination is a preventive medicine topic tested in PSM, pediatrics, and medicine — with specific schedules and indications that NEET PG tests directly.

Hepatitis B vaccine:

• Type: Recombinant DNA vaccine (HBsAg produced in yeast)
• Schedule (adults): 0, 1, 6 months (three doses)
• Schedule (neonates): Birth dose (within 24 hours), 6 weeks, 6 months (as part of pentavalent vaccine in NIS)
• Protective titer: Anti-HBs >10 mIU/mL
• Non-responders (<10 mIU/mL after 3 doses): Give another 3-dose series. If still no response, consider HBsAg testing (may be chronic carrier).

Hepatitis A vaccine:

• Type: Inactivated whole virus vaccine
• Schedule: 2 doses, 6–12 months apart
• Indication: Travelers to endemic areas, chronic liver disease, food handlers
• Not part of India's National Immunization Schedule (but recommended by IAP)

No vaccine available for: HCV (high genetic variability prevents vaccine development), HDV (prevented by HBV vaccination since HDV requires HBV co-infection)

NEET PG serology interpretation patterns

These are the most commonly tested serology-based vignettes — practice recognizing each pattern:

Pattern 1 — "All negative except anti-HBs" → Vaccinated individual (never infected, antibody from vaccine only)

Pattern 2 — "HBsAg positive, anti-HBc IgM positive, HBeAg positive" → Acute hepatitis B with active replication

Pattern 3 — "All negative except IgM anti-HBc" → Window period (the classic trap)

Pattern 4 — "Anti-HBs positive, anti-HBe positive, anti-HBc IgG positive" → Resolved past infection with natural immunity

Pattern 5 — "HBsAg positive for 8 months, HBeAg negative, anti-HBe positive, anti-HBc IgG positive" → Chronic HBV, inactive carrier (low replication)

Pattern 6 — "Anti-HCV positive, HCV RNA detectable" → Active hepatitis C infection (needs DAA therapy)

Pattern 7 — "Anti-HCV positive, HCV RNA undetectable" → Either resolved HCV (spontaneous clearance — 15–30%) or post-treatment cure (SVR)

Sources and references

1. Harrison's Principles of Internal Medicine, 21st Edition (Loscalzo et al., 2022) — Chapters on acute and chronic hepatitis, hepatic failure.
2. Jawetz, Melnick & Adelberg's Medical Microbiology, 28th Edition (Carroll et al., 2019) — Hepatitis virus classification, structure, and serology.
3. AASLD Practice Guidelines: Hepatitis B (Terrault et al., Hepatology 2018) — Treatment algorithms and serology interpretation.
4. WHO Guidelines on Hepatitis B and C Testing (2017) — Global screening and diagnostic protocols.
5. EASL Clinical Practice Guidelines: HCV Management (J Hepatol 2024) — DAA regimens and SVR endpoints.

Frequently asked questions

How many hepatitis questions appear in NEET PG?

Hepatitis contributes 3-5 questions per NEET PG paper across medicine, microbiology, pharmacology, and obstetrics. Hepatitis B serology interpretation is the single most predictable question — it appears in nearly every paper. HCV DAA therapy and hepatitis in pregnancy are increasingly tested since 2022.

How do I interpret hepatitis B serology in NEET PG?

The pattern tells the story: HBsAg positive with IgM anti-HBc indicates acute infection. HBsAg positive with IgG anti-HBc and HBeAg positive indicates chronic active hepatitis B. Anti-HBs positive alone indicates vaccination. Anti-HBs positive with anti-HBc positive indicates resolved natural infection. All markers negative means susceptible — needs vaccination.

What is the window period in hepatitis B?

The window period is the interval between disappearance of HBsAg and appearance of anti-HBs — typically 2-16 weeks. During this period, the only positive marker is IgM anti-HBc. This is the most commonly tested serology trap in NEET PG: a patient with isolated IgM anti-HBc positivity is in the window period of acute HBV infection.

What is the first-line treatment for chronic hepatitis C?

Pan-genotypic DAA (direct-acting antiviral) regimens are the first-line treatment. Sofosbuvir-velpatasvir for 12 weeks achieves SVR above 95% across all genotypes. Sofosbuvir-ledipasvir is used for genotype 1. Interferon-based therapy is obsolete. SVR12 (sustained virologic response at 12 weeks post-treatment) equals cure.

Which hepatitis virus is most dangerous in pregnancy?

Hepatitis E virus (HEV) carries the highest mortality in pregnancy — 15-25% mortality rate in the third trimester compared to below 1% in non-pregnant individuals. HEV is waterborne (fecal-oral), endemic in India, and causes fulminant hepatic failure in pregnant women. There is no specific antiviral treatment.

What drugs most commonly cause drug-induced hepatitis?

Isoniazid is the most commonly tested drug cause of hepatitis in NEET PG. Other high-yield hepatotoxic drugs include acetaminophen (dose-dependent, most common cause of acute liver failure in the West), rifampicin, pyrazinamide, halothane (halothane hepatitis), methotrexate (chronic fibrosis), and sodium valproate (Reye-like syndrome in children).

What is the hepatitis B vaccination schedule?

The standard schedule is 0, 1, 6 months (three doses) for adults. For neonates born to HBsAg-positive mothers: HBV vaccine + HBIG (hepatitis B immunoglobulin) within 12 hours of birth, then vaccine at 1 and 6 months. Anti-HBs titer above 10 mIU/mL indicates protective immunity. Booster not routinely recommended for immunocompetent individuals.

How do I differentiate acute from chronic hepatitis B?

Acute hepatitis B shows HBsAg positive with IgM anti-HBc (IgM class antibody indicates recent infection). Chronic hepatitis B shows HBsAg positive for more than 6 months with IgG anti-HBc. The persistence of HBsAg beyond 6 months defines chronicity. HBeAg status further divides chronic HBV into e-antigen positive (high replication) vs e-antigen negative.

Hepatitis serology is a pattern recognition skill — the more combinations you practice, the faster you will decode exam vignettes. Start drilling now.

Start practicing hepatology MCQs free →

See our pricing plans for unlimited access and create a personalized study plan covering the entire GI and hepatology syllabus.

---

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: March 2026

This article is reviewed by qualified medical professionals for clinical accuracy and exam relevance. For corrections or updates, contact the editorial team.